Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
ChEMBL ligand: CHEMBL1957266 |
---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
---|---|---|---|---|---|---|---|---|
bromodomain containing 1/Bromodomain-containing protein 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2176774] [GtoPdb: 2724] [UniProtKB: O95696] | ||||||||
ChEMBL | Inhibition of recombinant BRD1 (unknown origin) incubated for 120 mins by TR-FRET assay | B | 4.35 | pIC50 | 44500 | nM | IC50 | J Med Chem (2021) 64: 17413-17435 [PMID:34813314] |
bromodomain containing 2/Bromodomain-containing protein 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1293289] [GtoPdb: 1944] [UniProtKB: P25440] | ||||||||
ChEMBL | Inhibition of human 6x-His-tagged BRD2 bromodomain 1 expressed in Escherichia coli | B | 6.89 | pKd | 130 | nM | Kd | J Med Chem (2018) 61: 9316-9334 [PMID:30253095] |
ChEMBL | Binding affinity to BRD2-BD1 by isothermal titration calorimetry | B | 6.89 | pKd | 128.4 | nM | Kd | Bioorg Med Chem (2012) 20: 1887-1892 [PMID:22316554] |
ChEMBL | Binding affinity to His-tagged BRD2 bromodomain 2 (unknown origin) by SPR assay | B | 6.94 | pKd | 116 | nM | Kd | Bioorg Med Chem (2018) 26: 25-36 [PMID:29170024] |
ChEMBL | Binding affinity to BRD2 bromodomain 2 (348 to 455 residues) (unknown origin) by ITC | B | 6.95 | pKd | 112.14 | nM | Kd | Bioorg Med Chem (2018) 26: 25-36 [PMID:29170024] |
ChEMBL | Binding affinity to recombinant BRD2 BD1 (unknown origin) incubated for 1 hr by TR-FRET assay | B | 7.11 | pKd | 78 | nM | Kd | J Med Chem (2020) 63: 5242-5256 [PMID:32255647] |
ChEMBL | Binding affinity to recombinant BRD2 BD2 (unknown origin) incubated for 1 hr by TR-FRET assay | B | 7.28 | pKd | 52 | nM | Kd | J Med Chem (2020) 63: 5242-5256 [PMID:32255647] |
ChEMBL | Binding affinity to BRD2 D1 (unknown origin) assessed as dissociation constant by isothermal titration calorimetry | B | 7.47 | pKd | 34 | nM | Kd | J Med Chem (2022) 65: 2342-2360 [PMID:35007061] |
ChEMBL | Binding affinity to biotinylated BRD2 BD1 (72 to 205 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method | B | 7.83 | pKd | 14.7 | nM | Kd | J Med Chem (2015) 58: 4927-4939 [PMID:26080064] |
ChEMBL | Binding affinity to biotinylated BRD2 BD2 (349 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method | B | 8.21 | pKd | 6.2 | nM | Kd | J Med Chem (2015) 58: 4927-4939 [PMID:26080064] |
ChEMBL | Displacement of FAM-labeled ZBA248 from BRD2 BD1 (72 to 205 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay | B | 7.88 | pKi | 13.2 | nM | Ki | J Med Chem (2015) 58: 4927-4939 [PMID:26080064] |
ChEMBL | Inhibition of FAM-labeled ZBA248 binding to recombinant N-terminal His6-tagged BRD2 bromodomain 1 (72 to 205 residues) (unknown origin) expressed in Escherichia coli Rosetta2 DE3 after 30 mins by fluorescence polarization assay | B | 7.88 | pKi | 13.2 | nM | Ki | J Med Chem (2018) 61: 462-481 [PMID:28339196] |
ChEMBL | Displacement of FAM-labeled ZBA248 from BRD2 BD2 (349 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay | B | 7.9 | pKi | 12.5 | nM | Ki | J Med Chem (2015) 58: 4927-4939 [PMID:26080064] |
ChEMBL | Inhibition of FAM-labeled ZBA248 binding to recombinant N-terminal His6-tagged BRD2 bromodomain 2 (349 to 460 residues) (unknown origin) expressed in Escherichia coli Rosetta2 DE3 after 30 mins by fluorescence polarization assay | B | 7.9 | pKi | 12.5 | nM | Ki | J Med Chem (2018) 61: 462-481 [PMID:28339196] |
ChEMBL | Inhibition of recombinant BRD2 BD1 (unknown origin) incubated for 120 mins by TR-FRET assay | B | 6.41 | pIC50 | 392 | nM | IC50 | J Med Chem (2021) 64: 17413-17435 [PMID:34813314] |
ChEMBL | Inhibition of BRD2 BD1 (unknown origin) incubated for 2 hrs by TR-FRET assay | B | 6.73 | pIC50 | 185 | nM | IC50 | J Med Chem (2021) 64: 18025-18053 [PMID:34908415] |
ChEMBL | Inhibition of recombinant human BRD2 bromodomain 2 (342 to 460 residues) using biotin labeled peptide substrate preincubated for 15 mins followed by substrate addition measured after 1 hr by TR-FRET assay | B | 6.77 | pIC50 | 170 | nM | IC50 | Bioorg Med Chem (2018) 26: 25-36 [PMID:29170024] |
ChEMBL | Inhibition of human recombinant His-tagged BRD2 BD1 domain expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells by AlphaScreen assay | B | 6.81 | pIC50 | 155 | nM | IC50 | J Med Chem (2020) 63: 3678-3700 [PMID:32153186] |
ChEMBL | Inhibition of BRD2 D1 (unknown origin) by competitive fluorescence anisotropy assay | B | 6.85 | pIC50 | 140 | nM | IC50 | J Med Chem (2022) 65: 2342-2360 [PMID:35007061] |
ChEMBL | Inhibition of BRD2 D2 (unknown origin) by competitive fluorescence anisotropy assay | B | 6.92 | pIC50 | 120 | nM | IC50 | J Med Chem (2022) 65: 2342-2360 [PMID:35007061] |
ChEMBL | Inhibition of recombinant BRD2 BD2 (unknown origin) incubated for 120 mins by TR-FRET assay | B | 6.95 | pIC50 | 112 | nM | IC50 | J Med Chem (2021) 64: 17413-17435 [PMID:34813314] |
ChEMBL | Inhibition of BRD2 BD1 (unknown origin) after 1 hr by TR-FRET assay | B | 7.11 | pIC50 | 78 | nM | IC50 | Eur J Med Chem (2018) 151: 450-461 [PMID:29649741] |
ChEMBL | Binding affinity BRD2 BD1 (unknown origin) incubated for 1 hr by TR-FRET assay | B | 7.11 | pIC50 | 77 | nM | IC50 | J Med Chem (2022) 65: 2388-2408 [PMID:34982556] |
ChEMBL | Binding affinity BRD2 BD2 (unknown origin) incubated for 1 hr by TR-FRET assay | B | 7.27 | pIC50 | 54 | nM | IC50 | J Med Chem (2022) 65: 2388-2408 [PMID:34982556] |
ChEMBL | Inhibition of FAM-labeled ZBA248 binding to recombinant N-terminal His6-tagged BRD2 bromodomain 2 (349 to 460 residues) (unknown origin) expressed in Escherichia coli Rosetta2 DE3 after 30 mins by fluorescence polarization assay | B | 7.27 | pIC50 | 53.3 | nM | IC50 | J Med Chem (2018) 61: 462-481 [PMID:28339196] |
ChEMBL | Inhibition of BRD2 BD2 (unknown origin) after 1 hr by TR-FRET assay | B | 7.28 | pIC50 | 52 | nM | IC50 | Eur J Med Chem (2018) 151: 450-461 [PMID:29649741] |
ChEMBL | Inhibition of FAM-labeled ZBA248 binding to recombinant N-terminal His6-tagged BRD2 bromodomain 1 (72 to 205 residues) (unknown origin) expressed in Escherichia coli Rosetta2 DE3 after 30 mins by fluorescence polarization assay | B | 7.44 | pIC50 | 36.1 | nM | IC50 | J Med Chem (2018) 61: 462-481 [PMID:28339196] |
ChEMBL | Inhibition of BRD2 BD2 (unknown origin) incubated for 2 hrs by TR-FRET assay | B | 7.49 | pIC50 | 32 | nM | IC50 | J Med Chem (2021) 64: 18025-18053 [PMID:34908415] |
ChEMBL | Inhibition of BRD2 BD1 (unknown origin) preincubated for 15 mins followed by peptide addition and measured after 60 mins by TR-FRET assay | B | 7.54 | pIC50 | 29 | nM | IC50 | Eur J Med Chem (2020) 208: 112780-112780 [PMID:32883643] |
ChEMBL | Inhibition of BRD2 (unknown origin) by TR-FRET assay | B | 7.72 | pIC50 | 19 | nM | IC50 | Medchemcomm (2019) 10: 974-984 [PMID:31303996] |
ChEMBL | Inhibition of human recombinant His-tagged BRD2 BD2 domain expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells by AlphaScreen assay | B | 7.77 | pIC50 | 17 | nM | IC50 | J Med Chem (2020) 63: 3678-3700 [PMID:32153186] |
ChEMBL | Inhibition of BRD2 BD2 (unknown origin) preincubated for 15 mins followed by peptide addition and measured after 60 mins by TR-FRET assay | B | 8.17 | pIC50 | 6.7 | nM | IC50 | Eur J Med Chem (2020) 208: 112780-112780 [PMID:32883643] |
bromodomain containing 3/Bromodomain-containing protein 3 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1795186] [GtoPdb: 2725] [UniProtKB: Q15059] | ||||||||
ChEMBL | Inhibition of human 6x-His-tagged BRD3 bromodomain 2 expressed in Escherichia coli | B | 7.09 | pKd | 82 | nM | Kd | J Med Chem (2018) 61: 9316-9334 [PMID:30253095] |
ChEMBL | Binding affinity to BRD3-BD2 by isothermal titration calorimetry | B | 7.09 | pKd | 82 | nM | Kd | Bioorg Med Chem (2012) 20: 1887-1892 [PMID:22316554] |
ChEMBL | Binding affinity to recombinant BRD3 BD1 (unknown origin) incubated for 1 hr by TR-FRET assay | B | 7.09 | pKd | 81 | nM | Kd | J Med Chem (2020) 63: 5242-5256 [PMID:32255647] |
ChEMBL | Binding affinity to recombinant BRD3 BD2 (unknown origin) incubated for 1 hr by TR-FRET assay | B | 7.16 | pKd | 69 | nM | Kd | J Med Chem (2020) 63: 5242-5256 [PMID:32255647] |
ChEMBL | Binding affinity to BRD3-BD1 by isothermal titration calorimetry | B | 7.23 | pKd | 59.5 | nM | Kd | Bioorg Med Chem (2012) 20: 1887-1892 [PMID:22316554] |
ChEMBL | Inhibition of human 6x-His-tagged BRD3 bromodomain 1 expressed in Escherichia coli | B | 7.23 | pKd | 59 | nM | Kd | J Med Chem (2018) 61: 9316-9334 [PMID:30253095] |
ChEMBL | Binding affinity to biotinylated BRD3 BD1 (24 to 144 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method | B | 7.87 | pKd | 13.6 | nM | Kd | J Med Chem (2015) 58: 4927-4939 [PMID:26080064] |
ChEMBL | Binding affinity to biotinylated BRD3 BD2 (306 to 417 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method | B | 7.93 | pKd | 11.7 | nM | Kd | J Med Chem (2015) 58: 4927-4939 [PMID:26080064] |
ChEMBL | Displacement of FAM-labeled ZBA248 from BRD3 BD2 (306 to 417 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay | B | 8.05 | pKi | 8.9 | nM | Ki | J Med Chem (2015) 58: 4927-4939 [PMID:26080064] |
ChEMBL | Inhibition of FAM-labeled ZBA248 binding to recombinant N-terminal His6-tagged BRD3 bromodomain 2 (306 to 417residues) (unknown origin) expressed in Escherichia coli Rosetta2 DE3 after 30 mins by fluorescence polarization assay | B | 8.05 | pKi | 8.9 | nM | Ki | J Med Chem (2018) 61: 462-481 [PMID:28339196] |
ChEMBL | Displacement of FAM-labeled ZBA248 from BRD3 BD1 (24 to 144 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay | B | 8.18 | pKi | 6.6 | nM | Ki | J Med Chem (2015) 58: 4927-4939 [PMID:26080064] |
ChEMBL | Inhibition of FAM-labeled ZBA248 binding to recombinant N-terminal His6-tagged BRD3 bromodomain 1 (24 to 144 residues) (unknown origin) expressed in Escherichia coli Rosetta2 DE3 after 30 mins by fluorescence polarization assay | B | 8.18 | pKi | 6.6 | nM | Ki | J Med Chem (2018) 61: 462-481 [PMID:28339196] |
ChEMBL | Inhibition of recombinant BRD3 BD1 (unknown origin) incubated for 120 mins by TR-FRET assay | B | 6.89 | pIC50 | 129 | nM | IC50 | J Med Chem (2021) 64: 17413-17435 [PMID:34813314] |
ChEMBL | Inhibition of BRD3 D2 (unknown origin) by competitive fluorescence anisotropy assay | B | 7.02 | pIC50 | 96 | nM | IC50 | J Med Chem (2022) 65: 2342-2360 [PMID:35007061] |
ChEMBL | Inhibition of BRD3 BD1 (unknown origin) after 1 hr by TR-FRET assay | B | 7.09 | pIC50 | 81 | nM | IC50 | Eur J Med Chem (2018) 151: 450-461 [PMID:29649741] |
ChEMBL | Inhibition of BRD3 D1 (unknown origin) by competitive fluorescence anisotropy assay | B | 7.1 | pIC50 | <80 | nM | IC50 | J Med Chem (2022) 65: 2342-2360 [PMID:35007061] |
ChEMBL | Binding affinity BRD3 BD1 (unknown origin) incubated for 1 hr by TR-FRET assay | B | 7.1 | pIC50 | 79 | nM | IC50 | J Med Chem (2022) 65: 2388-2408 [PMID:34982556] |
ChEMBL | Inhibition of BRD3 BD1 (unknown origin) incubated for 2 hrs by TR-FRET assay | B | 7.12 | pIC50 | 76 | nM | IC50 | J Med Chem (2021) 64: 18025-18053 [PMID:34908415] |
ChEMBL | Binding affinity BRD3 BD2 (unknown origin) incubated for 1 hr by TR-FRET assay | B | 7.14 | pIC50 | 72 | nM | IC50 | J Med Chem (2022) 65: 2388-2408 [PMID:34982556] |
ChEMBL | Inhibition of BRD3 BD2 (unknown origin) after 1 hr by TR-FRET assay | B | 7.16 | pIC50 | 69 | nM | IC50 | Eur J Med Chem (2018) 151: 450-461 [PMID:29649741] |
ChEMBL | Inhibition of human recombinant His-tagged BRD3 BD1 domain expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells by AlphaScreen assay | B | 7.19 | pIC50 | 64 | nM | IC50 | J Med Chem (2020) 63: 3678-3700 [PMID:32153186] |
ChEMBL | Inhibition of BRD3 BD2 (unknown origin) incubated for 2 hrs by TR-FRET assay | B | 7.21 | pIC50 | 61 | nM | IC50 | J Med Chem (2021) 64: 18025-18053 [PMID:34908415] |
ChEMBL | Inhibition of FAM-labeled ZBA248 binding to recombinant N-terminal His6-tagged BRD3 bromodomain 2 (306 to 417residues) (unknown origin) expressed in Escherichia coli Rosetta2 DE3 after 30 mins by fluorescence polarization assay | B | 7.25 | pIC50 | 56.7 | nM | IC50 | J Med Chem (2018) 61: 462-481 [PMID:28339196] |
ChEMBL | Inhibition of recombinant BRD3 BD2 (unknown origin) incubated for 120 mins by TR-FRET assay | B | 7.28 | pIC50 | 53 | nM | IC50 | J Med Chem (2021) 64: 17413-17435 [PMID:34813314] |
ChEMBL | Inhibition of FAM-labeled ZBA248 binding to recombinant N-terminal His6-tagged BRD3 bromodomain 1 (24 to 144 residues) (unknown origin) expressed in Escherichia coli Rosetta2 DE3 after 30 mins by fluorescence polarization assay | B | 7.41 | pIC50 | 39.1 | nM | IC50 | J Med Chem (2018) 61: 462-481 [PMID:28339196] |
ChEMBL | Inhibition of human recombinant His-tagged BRD3 BD2 domain expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells by AlphaScreen assay | B | 7.41 | pIC50 | 39 | nM | IC50 | J Med Chem (2020) 63: 3678-3700 [PMID:32153186] |
ChEMBL | Inhibition of BRD3 (unknown origin) by TR-FRET assay | B | 7.64 | pIC50 | 23 | nM | IC50 | Medchemcomm (2019) 10: 974-984 [PMID:31303996] |
bromodomain containing 4/Bromodomain-containing protein 4 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1163125] [GtoPdb: 1945] [UniProtKB: O60885] | ||||||||
ChEMBL | Binding affinity to BRD4 C-terminal bromodomain 2 H437D mutant (unknown origin) expressed in Escherichia coli Bl21(DE3) by fluorescence polarization assay | B | 6.7 | pKd | 200 | nM | Kd | J Med Chem (2018) 61: 9316-9334 [PMID:30253095] |
ChEMBL | Binding affinity to BRD4 D2 (unknown origin) assessed as dissociation constant by isothermal titration calorimetry | B | 6.89 | pKd | 130 | nM | Kd | J Med Chem (2022) 65: 2342-2360 [PMID:35007061] |
ChEMBL | Binding affinity to BRD4 C-terminal bromodomain 2 (unknown origin) expressed in Escherichia coli Bl21(DE3) | B | 6.92 | pKd | 120 | nM | Kd | J Med Chem (2018) 61: 9316-9334 [PMID:30253095] |
ChEMBL | Binding affinity to human BRD4 expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells by isothermal titration calorimetry-based assay | B | 7 | pKd | 100 | nM | Kd | J Med Chem (2018) 61: 504-513 [PMID:28595007] |
ChEMBL | Binding affinity to recombinant BRD4 BD1 (unknown origin) incubated for 1 hr by TR-FRET assay | B | 7.04 | pKd | 92 | nM | Kd | J Med Chem (2020) 63: 5242-5256 [PMID:32255647] |
ChEMBL | Binding affinity to human His6-tagged BRD4 BD1 (N44 to E168 residues) expressed in Escherichia coli BL21 (DE3) cells by isothermal titration calorimetry method | B | 7.04 | pKd | 92 | nM | Kd | ACS Med Chem Lett (2018) 9: 262-267 [PMID:29541371] |
ChEMBL | Binding affinity to BRD4-BD2 by isothermal titration calorimetry | B | 7.05 | pKd | 90.1 | nM | Kd | Bioorg Med Chem (2012) 20: 1887-1892 [PMID:22316554] |
ChEMBL | Inhibition of human 6x-His-tagged BRD4 bromodomain 2 expressed in Escherichia coli | B | 7.05 | pKd | 90 | nM | Kd | J Med Chem (2018) 61: 9316-9334 [PMID:30253095] |
ChEMBL | Binding affinity to recombinant human N-terminal hexaHis-tagged BRD4 expressed in Escherichia coli BL21 (DE3) cells by ITC analysis | B | 7.15 | pKd | 71 | nM | Kd | J Med Chem (2021) 64: 15772-15786 [PMID:34710325] |
ChEMBL | Binding affinity to recombinant BRD4 BD2 (unknown origin) incubated for 1 hr by TR-FRET assay | B | 7.21 | pKd | 62 | nM | Kd | J Med Chem (2020) 63: 5242-5256 [PMID:32255647] |
ChEMBL | Binding affinity to BRD4 by isothermal titration calorimetry | B | 7.22 | pKd | 60 | nM | Kd | Bioorg Med Chem (2012) 20: 1878-1886 [PMID:22137933] |
GtoPdb | Displacement binding constant to recombinant BRD4-BD1 protein. | - | 7.3 | pKd | 50 | nM | Kd | Nature (2010) 468: 1067-73 [PMID:20871596] |
ChEMBL | Binding affinity to BRD4 bromodomain 1 (unknown origin) by isothermal titration calorimetry | B | 7.3 | pKd | 50 | nM | Kd | Medchemcomm (2018) 9: 1779-1802 [PMID:30542529] |
ChEMBL | Binding affinity to BRD4-BD1 by isothermal titration calorimetry | B | 7.31 | pKd | 49 | nM | Kd | Bioorg Med Chem (2012) 20: 1887-1892 [PMID:22316554] |
ChEMBL | Binding affinity to BRD4 isoform 1 | B | 7.31 | pKd | 49 | nM | Kd | J Med Chem (2012) 55: 9393-9413 [PMID:22924434] |
ChEMBL | Inhibition of human 6x-His-tagged BRD4 bromodomain 1 expressed in Escherichia coli | B | 7.31 | pKd | 49 | nM | Kd | J Med Chem (2018) 61: 9316-9334 [PMID:30253095] |
ChEMBL | Binding affinity to BRD4 (unknown origin) | B | 7.31 | pKd | 49 | nM | Kd | Bioorg Med Chem Lett (2020) 30: 126958-126958 [PMID:32019712] |
ChEMBL | Binding affinity to BRD4-BD1 by isothermal titration calorimetry | B | 7.31 | pKd | 49 | nM | Kd | Bioorg Med Chem (2012) 20: 1878-1886 [PMID:22137933] |
ChEMBL | Binding affinity to recombinant human N-terminal hexaHis-tagged BRD4 expressed in Escherichia coli BL21 (DE3) cells by MST assay | B | 7.46 | pKd | 35 | nM | Kd | J Med Chem (2021) 64: 15772-15786 [PMID:34710325] |
ChEMBL | Binding affinity to human His6-tagged BRD4 bromodomain 1 (N44 to E168 residues) expressed in Escherichia coli BL21(DE3) cells by isothermal titration calorimetry | B | 7.47 | pKd | 34 | nM | Kd | J Med Chem (2016) 59: 1565-1579 [PMID:26731490] |
ChEMBL | Binding affinity to BRD4 D1 (unknown origin) assessed as dissociation constant by isothermal titration calorimetry | B | 7.72 | pKd | 19 | nM | Kd | J Med Chem (2022) 65: 2342-2360 [PMID:35007061] |
ChEMBL | Binding affinity to human BRD4 BD1 (N44 to E168 aa residues) by bromoKdELECT Discover assay | B | 7.89 | pKd | 13 | nM | Kd | J Med Chem (2020) 63: 15603-15620 [PMID:33275431] |
ChEMBL | Binding affinity to biotinylated BRD4 BD1 (44 to 168 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method | B | 7.89 | pKd | 12.8 | nM | Kd | J Med Chem (2015) 58: 4927-4939 [PMID:26080064] |
ChEMBL | Binding affinity to recombinant human N-terminal hexaHis-tagged BRD4 expressed in Escherichia coli BL21 (DE3) cells by qPCR assay | B | 8.09 | pKd | 8.2 | nM | Kd | J Med Chem (2021) 64: 15772-15786 [PMID:34710325] |
ChEMBL | Binding affinity to biotinylated BRD4 BD2 (333 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method | B | 8.17 | pKd | 6.7 | nM | Kd | J Med Chem (2015) 58: 4927-4939 [PMID:26080064] |
ChEMBL | Binding affinity to human N-terminal His6-tagged BRD4 BD1-BD2 (K57 to K550 residues) after 1 hr using alexa-647 conjugated probe by TR-FRET assay | B | 7.11 | pKi | 77 | nM | Ki | J Med Chem (2017) 60: 8369-8384 [PMID:28949521] |
ChEMBL | Inhibition of FAM-labeled ZBA248 binding to recombinant N-terminal His6-tagged BRD4 bromodomain 1 (44 to 168 residues) (unknown origin) expressed in Escherichia coli Rosetta2 DE3 after 30 mins by fluorescence polarization assay | B | 7.83 | pKi | 14.9 | nM | Ki | J Med Chem (2018) 61: 462-481 [PMID:28339196] |
ChEMBL | Inhibition of FAM-labeled ZBA248 binding to recombinant human N-terminal His6-tagged BRD4 bromodomain 1 (44 to 168 residues) expressed in Rosetta2 DE3 cells after 30 mins by Flourescence polarization assay | B | 7.83 | pKi | 14.9 | nM | Ki | J Med Chem (2017) 60: 3887-3901 [PMID:28463487] |
ChEMBL | Inhibition of FAM-labeled ZBA248 binding to recombinant human N-terminal His6-tagged BRD4 bromodomain 2 (333 to 460 residues) expressed in Rosetta2 DE3 cells after 30 mins by Flourescence polarization assay | B | 7.92 | pKi | 12 | nM | Ki | J Med Chem (2017) 60: 3887-3901 [PMID:28463487] |
ChEMBL | Inhibition of FAM-labeled ZBA248 binding to recombinant N-terminal His6-tagged BRD4 bromodomain 2 (333 to 460 residues) (unknown origin) expressed in Escherichia coli Rosetta2 DE3 after 30 mins by fluorescence polarization assay | B | 7.92 | pKi | 12 | nM | Ki | J Med Chem (2018) 61: 462-481 [PMID:28339196] |
ChEMBL | Displacement of FAM-labeled ZBA248 from BRD4 BD2 (333 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay | B | 7.97 | pKi | 10.7 | nM | Ki | J Med Chem (2015) 58: 4927-4939 [PMID:26080064] |
ChEMBL | Displacement of FAM-labeled ZBA248 from BRD4 BD1 (44 to 168 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay | B | 8.12 | pKi | 7.6 | nM | Ki | J Med Chem (2015) 58: 4927-4939 [PMID:26080064] |
ChEMBL | Binding affinity to human BRD4 BD1 (44 to 168 residues) by fluorescence polarization assay | B | 8.28 | pKi | 5.3 | nM | Ki | J Med Chem (2018) 61: 6685-6704 [PMID:30019901] |
ChEMBL | Inhibition of BRD4 (unknown origin) by biotinylated-JQ1 based AlphaScreen BRD binding assay | B | 4.09 | pIC50 | 81500 | nM | IC50 | J Med Chem (2014) 57: 9019-9027 [PMID:25314271] |
ChEMBL | Inhibition of BRD4 in human SAE cells assessed as reduction in TLR3 agonist poly(I:C) -induced ISG56 RNA expression preincubated for 24 hrs followed by poly(I:C) addition and measured after 4 hrs by SYBR green dye-based qRT-PCR analysis | B | 5.79 | pIC50 | 1630 | nM | IC50 | Eur J Med Chem (2018) 151: 450-461 [PMID:29649741] |
ChEMBL | Inhibition of BRD4 in human SAE cells assessed as reduction in TLR3 agonist poly(I:C) -induced IL-8 RNA expression preincubated for 24 hrs followed by poly(I:C) addition and measured after 4 hrs by SYBR green dye-based qRT-PCR analysis | B | 5.82 | pIC50 | 1510 | nM | IC50 | Eur J Med Chem (2018) 151: 450-461 [PMID:29649741] |
ChEMBL | Inhibition of BRD4 in human SAE cells assessed as reduction in TLR3 agonist poly(I:C) -induced grobeta RNA expression preincubated for 24 hrs followed by poly(I:C) addition and measured after 4 hrs by SYBR green dye-based qRT-PCR analysis | B | 5.83 | pIC50 | 1490 | nM | IC50 | Eur J Med Chem (2018) 151: 450-461 [PMID:29649741] |
ChEMBL | Inhibition of BRD4 in human SAE cells assessed as reduction in TLR3 agonist poly(I:C) -induced ISG54 RNA expression preincubated for 24 hrs followed by poly(I:C) addition and measured after 4 hrs by SYBR green dye-based qRT-PCR analysis | B | 5.86 | pIC50 | 1380 | nM | IC50 | Eur J Med Chem (2018) 151: 450-461 [PMID:29649741] |
ChEMBL | Inhibition of BRD4 in poly(I:C)-stimulated human SAECs TLR3-inducible IL-6 gene expression pre-incubated for 24 hrs before poly(I:C) stimulation for 4 hrs by qRT-PCR analysis | B | 5.99 | pIC50 | 1020 | nM | IC50 | J Med Chem (2020) 63: 5242-5256 [PMID:32255647] |
ChEMBL | Inhibition of BRD4 in poly(I:C)-stimulated human SAECs TLR3-inducible CIG5 gene expression pre-incubated for 24 hrs before poly(I:C) stimulation for 4 hrs by qRT-PCR analysis | B | 6.02 | pIC50 | 950 | nM | IC50 | J Med Chem (2020) 63: 5242-5256 [PMID:32255647] |
ChEMBL | Inhibition of recombinant human N-terminal His-tagged BRD4 bromodomain 1 (49 to 170 residues) expressed in Escherichia coli using biotinylated peptide containing acetylated lysine as substrate pretreated for 15 mins followed by substrate addition after 1 hr by TR-FRET assay | B | 6.09 | pIC50 | 820 | nM | IC50 | Bioorg Med Chem (2017) 25: 3677-3684 [PMID:28549889] |
ChEMBL | Displacement of Fl-JQ1 from BRD4 C-terminal bromodomain 2 H437D mutant (unknown origin) expressed in Escherichia coli Bl21(DE3) by fluorescence polarization assay | B | 6.23 | pIC50 | 590 | nM | IC50 | J Med Chem (2018) 61: 9316-9334 [PMID:30253095] |
ChEMBL | Inhibition of BRD4 bromodomain 2 (unknown origin) expressed in Escherichia coli Bl21(DE3) by fluorescence anisotropy | B | 6.31 | pIC50 | 490 | nM | IC50 | J Med Chem (2018) 61: 9316-9334 [PMID:30253095] |
ChEMBL | Inhibition of fluorescent-tagged ligand from nanoLuc fused full length BRD4 (unknown origin) expressed in 293T cells by luciferase reporter gene based BRET engagement assay | B | 6.52 | pIC50 | 300 | nM | IC50 | J Med Chem (2018) 61: 9301-9315 [PMID:30289257] |
ChEMBL | Displacement of APC-labeled biotinylated-avidin from Euphorium-chelated recombinant human BRD4 bromodomain 1 expressed in Escherichia coli preincubated for 15 mins followed by APC-labeled biotinylated-avidin addition and measured after 1 hr under dark condition by TR-FRET assay | B | 6.7 | pIC50 | 199 | nM | IC50 | J Med Chem (2020) 63: 7186-7210 [PMID:32453591] |
ChEMBL | Inhibition of biotinylated H4 K5,8,12,16Ac peptide binding to GST-tagged BRD4 bromodomain1 (unknown origin) measured after 60 mins by AlphaScreen assay | B | 6.77 | pIC50 | 170 | nM | IC50 | Bioorg Med Chem (2019) 27: 1871-1881 [PMID:30926312] |
ChEMBL | Inhibition of BRD4 (unknown origin) by TR-FRET assay | B | 6.84 | pIC50 | 144 | nM | IC50 | Medchemcomm (2019) 10: 974-984 [PMID:31303996] |
ChEMBL | Displacement of APC-labeled biotinylated-avidin from Euphorium-chelated recombinant human BRD4 bromodomain 2 expressed in Escherichia coli preincubated for 15 mins followed by APC-labeled biotinylated-avidin addition and measured after 1 hr under dark condition by TR-FRET assay | B | 6.9 | pIC50 | 126 | nM | IC50 | J Med Chem (2020) 63: 7186-7210 [PMID:32453591] |
ChEMBL | Displacement of FITC-conjugated JQ1 from BRD4 BD2 (unknown origin) expressed in Escherichia coli BL21-DE3 rosetta cells incubated for 15 mins by competitive fluorescence polarization assay | B | 6.91 | pIC50 | 123 | nM | IC50 | J Med Chem (2021) 64: 11637-11650 [PMID:34279939] |
ChEMBL | Inhibition of His6-tagged human BRD4 bromodomain-1 (N44 to E168 residues) expressed in Escherichia coli BL21(DE3) using biotinylated-H4KAc4 as substrate by AlphaScreen assay | B | 6.92 | pIC50 | 120 | nM | IC50 | Eur J Med Chem (2018) 152: 542-559 [PMID:29758518] |
ChEMBL | Inhibition of human His6-tagged BRD4 BD1 (N44 to E168 residues) expressed in Escherichia coli BL21 (DE3) cells using H-SGRGK(Ac)GGK(Ac)GLGK(Ac)GGAK(Ac)RHRK-Biotin-OH as substrate after 2.5 hrs by AlphaScreen assay | B | 6.92 | pIC50 | 120 | nM | IC50 | ACS Med Chem Lett (2018) 9: 262-267 [PMID:29541371] |
ChEMBL | Inhibition of human His6-tagged BRD4 bromodomain 1 (N44 to E168 residues) expressed in Escherichia coli BL21(DE3) cells using biotin-H4KAc4 as substrate incubated for 2 hrs by alphascreen assay | B | 6.92 | pIC50 | 120 | nM | IC50 | J Med Chem (2016) 59: 1565-1579 [PMID:26731490] |
ChEMBL | Inhibition of BRD4 D2 (unknown origin) by competitive fluorescence anisotropy assay | B | 7.03 | pIC50 | 94 | nM | IC50 | J Med Chem (2022) 65: 2342-2360 [PMID:35007061] |
ChEMBL | Binding affinity recombinant human BRD4 BD1 (42 to 168 residues) expressed in Escherichia coli BL21(DE3) incubated for 1 hr by TR-FRET assay | B | 7.04 | pIC50 | 92 | nM | IC50 | J Med Chem (2022) 65: 2388-2408 [PMID:34982556] |
ChEMBL | Inhibition of BRD4 BD1 (unknown origin) incubated for 2 hrs by TR-FRET assay | B | 7.04 | pIC50 | 92 | nM | IC50 | J Med Chem (2021) 64: 18025-18053 [PMID:34908415] |
ChEMBL | Inhibition of BRD4 D1 (unknown origin) by competitive fluorescence anisotropy assay | B | 7.04 | pIC50 | <92 | nM | IC50 | J Med Chem (2022) 65: 2342-2360 [PMID:35007061] |
ChEMBL | Inhibition of BRD4 BD1 (unknown origin) after 1 hr by TR-FRET assay | B | 7.04 | pIC50 | 92 | nM | IC50 | Eur J Med Chem (2018) 151: 450-461 [PMID:29649741] |
ChEMBL | Inhibition of human His-tagged BRD4 BD1 (49 to 170 residues) using H-SGRGK(Ac)GGK(Ac)GLGK-(Ac)GGAK(Ac)RHRK(Biotin)-OH as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by TR-FRET assay | B | 7.04 | pIC50 | 91 | nM | IC50 | Eur J Med Chem (2016) 121: 294-299 [PMID:27266999] |
ChEMBL | Inhibition of BRD4 bromodomain 1/2 (unknown origin) by alphascreen assay | B | 7.05 | pIC50 | 90 | nM | IC50 | Bioorg Med Chem Lett (2019) 29: 126577-126577 [PMID:31421967] |
ChEMBL | Inhibition of human BRD4 expressed in Escherichia coli BL21(DE3)-R3-pRARE2 by bromodomain alphascreen peptide displacement assay | B | 7.05 | pIC50 | 90 | nM | IC50 | Bioorg Med Chem Lett (2016) 26: 2931-2935 [PMID:27142751] |
ChEMBL | Inhibition of recombinant BRD4 BD2 (unknown origin) incubated for 120 mins by TR-FRET assay | B | 7.05 | pIC50 | 89 | nM | IC50 | J Med Chem (2021) 64: 17413-17435 [PMID:34813314] |
ChEMBL | Inhibition of BRD4-BD1 (44 to 168 residues) (unknown origin) using histone H4 peptide as substrate preincubated for 15 mins followed by addition of substrate measured after 60 mins by AlphaScreen assay | B | 7.06 | pIC50 | 88 | nM | IC50 | Bioorg Med Chem (2017) 25: 2482-2490 [PMID:28314513] |
ChEMBL | Inhibition of BRD4-BD2 (333 to 460 residues) (unknown origin) using histone H4 peptide as substrate preincubated for 15 mins followed by addition of substrate measured after 60 mins by AlphaScreen assay | B | 7.06 | pIC50 | 87 | nM | IC50 | Bioorg Med Chem (2017) 25: 2482-2490 [PMID:28314513] |
ChEMBL | Inhibition of BRD4 bromodomain1 (unknown origin) using peptide H4 as substrate incubated for 15 mins followed by substrate addition and measured after 1 hr by alphascreen assay | B | 7.06 | pIC50 | 87 | nM | IC50 | ACS Med Chem Lett (2019) 10: 1680-1685 [PMID:31857846] |
ChEMBL | Inhibition of BRD4 in human HL60 cells assessed as reduction in C-myc production after 24 hrs by ELISA | B | 7.07 | pIC50 | 86 | nM | IC50 | Bioorg Med Chem (2017) 25: 3677-3684 [PMID:28549889] |
ChEMBL | Inhibition of BRD4 BD1/BD2 (unknown origin) incubated for 2 hrs by TR-FRET assay | B | 7.08 | pIC50 | 84 | nM | IC50 | J Med Chem (2021) 64: 18025-18053 [PMID:34908415] |
ChEMBL | Inhibition of recombinant BRD4 (unknown origin) incubated for 120 mins by TR-FRET assay | B | 7.08 | pIC50 | 83 | nM | IC50 | J Med Chem (2021) 64: 17413-17435 [PMID:34813314] |
ChEMBL | Inhibition of biotinylated H4 K5,8,12,16Ac peptide binding to GST-tagged BRD4 bromodomain2 (unknown origin) measured after 60 mins by AlphaScreen assay | B | 7.1 | pIC50 | 80 | nM | IC50 | Bioorg Med Chem (2019) 27: 1871-1881 [PMID:30926312] |
ChEMBL | Inhibition of BRD4 bromodomain2 (unknown origin) using peptide H4 as substrate incubated for 15 mins followed by substrate addition and measured after 1 hr by alphascreen assay | B | 7.1 | pIC50 | 79 | nM | IC50 | ACS Med Chem Lett (2019) 10: 1680-1685 [PMID:31857846] |
ChEMBL | Inhibition of BRD4 bromodomain-1 (unknown origin) by AlphaScreen assay | B | 7.11 | pIC50 | 77 | nM | IC50 | Eur J Med Chem (2018) 152: 542-559 [PMID:29758518] |
ChEMBL | Binding affinity to first bromodomain of BRD4 | B | 7.11 | pIC50 | 77 | nM | IC50 | ACS Med Chem Lett (2012) 3: 691-694 [PMID:24900532] |
ChEMBL | Displacement of H4(1-21)KAc5,8,12,16 peptide from BRD4 isoform 1 bead based amplified luminescent proximity homogeneous assay | B | 7.11 | pIC50 | 77 | nM | IC50 | J Med Chem (2012) 55: 9393-9413 [PMID:22924434] |
ChEMBL | Inhibition of human N-terminal BRD4 bromodomain expressed in Escherichia coli BL21(DE3) after 30 mins by luminescence proximity homogeneous assay | B | 7.11 | pIC50 | 77 | nM | IC50 | J Med Chem (2012) 55: 587-596 [PMID:22136469] |
ChEMBL | Binding affinity to human BRD4 bromodomain 1 using H4Ac4 peptide by amplified luminescent proximity homogeneous assay | B | 7.11 | pIC50 | 77 | nM | IC50 | J Med Chem (2013) 56: 3217-3227 [PMID:23517011] |
ChEMBL | Inhibition of BRD4 bromodomain 1 (unknown origin)-acetylated histone H4 interaction by luminescence proximity homogeneous assay | B | 7.11 | pIC50 | 77 | nM | IC50 | Medchemcomm (2012) 3: 123-134 |
ChEMBL | Inhibition of human His-tagged BRD4 bromodomain 1 expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells using biotin-H4K5acK8acK12acK16ac as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by alphascreen assay | B | 7.11 | pIC50 | 77 | nM | IC50 | J Med Chem (2016) 59: 1565-1579 [PMID:26731490] |
ChEMBL | Inhibition of BRD4(1) (unknown origin) | B | 7.11 | pIC50 | 77 | nM | IC50 | Bioorg Med Chem Lett (2016) 26: 2931-2935 [PMID:27142751] |
ChEMBL | Inhibition of recombinant human His6-tagged BRD4 bromodomain 1 expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells preincubated for 30 mins followed by H4K5acK8acK12acK16ac peptide substrate addition after 30 mins by alphascreen assay | B | 7.11 | pIC50 | 77 | nM | IC50 | J Med Chem (2017) 60: 4533-4558 [PMID:28195723] |
ChEMBL | Inhibition of recombinant His-tagged human BRD4 bromodomain 1 expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells preincubated for 30 mins followed by H4K5acK8acK12acK16ac substrate addition measured after 30 mins by AlphaScreen assay | B | 7.11 | pIC50 | 77 | nM | IC50 | Bioorg Med Chem (2018) 26: 2937-2957 [PMID:29776834] |
ChEMBL | Displacement of acetylated histone peptide from BRD4-BD1 by luminescence proximity homogenous assay | B | 7.11 | pIC50 | 77 | nM | IC50 | Bioorg Med Chem (2012) 20: 1887-1892 [PMID:22316554] |
ChEMBL | Inhibition of BRD4 bromodomain 1 (unknown origin) by alpha-screen method | B | 7.11 | pIC50 | 77 | nM | IC50 | Medchemcomm (2018) 9: 1779-1802 [PMID:30542529] |
ChEMBL | Inhibition of HSGRGK(Ac)GGK(Ac)GLGK(Ac)GGAK(Ac)RHRK(Biotin)-OH binding to recombinant human His6-tagged BRD4 bromodomain 1 expressed in Escherichia coli BL21 (DE3)-R3-pRARE2 cells preincubated for 30 mins followed by HSGRGK(Ac)GGK(Ac)GLGK(Ac)GGAK(Ac)RHRK(Biotin)-OH addition and measured after 30 mins by Alphascreen assay | B | 7.11 | pIC50 | 77 | nM | IC50 | J Med Chem (2020) 63: 3956-3975 [PMID:32208600] |
ChEMBL | Inhibition of BRD4 (unknown origin) | B | 7.11 | pIC50 | 77 | nM | IC50 | Bioorg Med Chem Lett (2020) 30: 126958-126958 [PMID:32019712] |
ChEMBL | Inhibition of human His-tagged BRD4 BD1 domain using H4K5acK8acK12acK16ac as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by AlphaScreen assay | B | 7.11 | pIC50 | 77 | nM | IC50 | Eur J Med Chem (2020) 208: 112780-112780 [PMID:32883643] |
ChEMBL | Inhibition of HYSGRGK(Ac)GGK(Ac)GLGK(Ac)GGAK(Ac)RHRK(Biotin)-OH binding to recombinant human His6-tagged BRD4 bromodomain 1 (N44 to E168 residues) expressed in Escherichia coli BL21 (DE3) cells measured after 2 hrs by Alphascreen assay | B | 7.11 | pIC50 | 77 | nM | IC50 | J Med Chem (2018) 61: 3037-3058 [PMID:29566488] |
ChEMBL | Binding affinity to BRD4 BD1 (unknown origin) by fluorescence anisotropy method | B | 7.11 | pIC50 | 77 | nM | IC50 | J Med Chem (2021) 64: 10497-10511 [PMID:34236185] |
ChEMBL | Displacement of APC-labeled biotinylated-avidin from Euphorium-chelated recombinant human N-terminal GST-tagged BRD4 bromodomain 1 expressed in Escherichia coli preincubated for 15 mins followed by APC-labeled biotinylated-avidin addition and measured after 1 hr under dark condition by TR-FRET assay | B | 7.13 | pIC50 | 74 | nM | IC50 | Bioorg Med Chem (2020) 28: 115601-115601 [PMID:32631570] |
ChEMBL | Binding affinity to BRD4 BD2 (unknown origin) by fluorescence anisotropy method | B | 7.14 | pIC50 | 72 | nM | IC50 | J Med Chem (2021) 64: 10497-10511 [PMID:34236185] |
ChEMBL | Inhibition of JQ1-FITC binding to His6-tagged BRD4-BD1 (unknown origin) expressed in Escherichia coli BL21 (DE3)-codon plus-RIL cells incubated in dark for 4 hrs by fluorescence anisotropy assay | B | 7.15 | pIC50 | 70 | nM | IC50 | Eur J Med Chem (2017) 137: 176-195 [PMID:28586718] |
ChEMBL | Inhibition of BRD4 in human Raji cells assessed as reduction of MYC expression after 4 hrs | B | 7.16 | pIC50 | 69 | nM | IC50 | ACS Med Chem Lett (2013) 4: 835-840 [PMID:24900758] |
ChEMBL | Inhibition of human recombinant His-tagged BRD4 BD2 domain using H-SGRGK(Ac)GGK(Ac)GLGK-(Ac)GGAK(Ac)RHRK(Biotin)-OH as substrate preincubated with enzyme for 30 mins followed by substrate addition measured after 30 mins by AlphaScreen assay | B | 7.16 | pIC50 | 69 | nM | IC50 | J Med Chem (2020) 63: 3678-3700 [PMID:32153186] |
ChEMBL | Binding affinity to recombinant human N-terminal His-tagged BRD4 BD1 (44 to 170 residues) expressed in Escherichia coli using H4K5AcK8Ac as substrate measured after 30 mins by AlphaScreen assay | B | 7.2 | pIC50 | 62.57 | nM | IC50 | Bioorg Med Chem (2020) 28: 115181-115181 [PMID:31767403] |
ChEMBL | Inhibition of BRD4 BD2 (unknown origin) after 1 hr by TR-FRET assay | B | 7.21 | pIC50 | 62 | nM | IC50 | Eur J Med Chem (2018) 151: 450-461 [PMID:29649741] |
ChEMBL | Binding affinity human BRD4 BD2 incubated for 1 hr by TR-FRET assay | B | 7.21 | pIC50 | 62 | nM | IC50 | J Med Chem (2022) 65: 2388-2408 [PMID:34982556] |
ChEMBL | Inhibition of N-terminal His-tagged BRD4 (BD1) (unknown origin) using biotinylated tetra-acetylated histone H4 peptide after 30 mins by alpha-screen assay | B | 7.22 | pIC50 | 60 | nM | IC50 | J Med Chem (2018) 61: 8202-8211 [PMID:30165024] |
ChEMBL | Inhibition of BRD4-BD1 in human Raji cells assessed as downregulation of MYC gene expression by PCR method | B | 7.22 | pIC50 | 60 | nM | IC50 | Bioorg Med Chem Lett (2018) 28: 1811-1816 [PMID:29657099] |
ChEMBL | Inhibition of BRD4(1) (unknown origin) incubated for 4 hrs by (+)-JQ1 fluorescent ligand based fluorescence anisotrophy | B | 7.24 | pIC50 | 58 | nM | IC50 | J Med Chem (2015) 58: 1281-1297 [PMID:25559428] |
ChEMBL | Inhibition of BRD4 D1 (unknown origin) by alphascreen assay | B | 7.29 | pIC50 | 51 | nM | IC50 | J Med Chem (2022) 65: 2342-2360 [PMID:35007061] |
ChEMBL | Displacement of (+)-JQ1 from 6H-Thr BRD4 Y97A mutant BD2 (unknown origin) after 30 mins by TR-FRET assay | B | 7.3 | pIC50 | 50.12 | nM | IC50 | J Med Chem (2018) 61: 4317-4334 [PMID:29656650] |
ChEMBL | Inhibition of N-terminal His-tagged BRD4 (BD1/BD2) (unknown origin) using biotinylated tetra-acetylated histone H4 peptide after 30 mins by alpha-screen assay | B | 7.3 | pIC50 | 50 | nM | IC50 | J Med Chem (2018) 61: 8202-8211 [PMID:30165024] |
ChEMBL | Displacement of FITC-conjugated JQ1 from wildtype BRD4 BD1 (unknown origin) expressed in Escherichia coli BL21-DE3 rosetta cells incubated for 15 mins by competitive fluorescence polarization assay | B | 7.31 | pIC50 | 49 | nM | IC50 | J Med Chem (2021) 64: 11637-11650 [PMID:34279939] |
ChEMBL | Inhibition of FAM-labeled ZBA248 binding to recombinant N-terminal His6-tagged BRD4 bromodomain 1 (44 to 168 residues) (unknown origin) expressed in Escherichia coli Rosetta2 DE3 after 30 mins by fluorescence polarization assay | B | 7.33 | pIC50 | 46.7 | nM | IC50 | J Med Chem (2018) 61: 462-481 [PMID:28339196] |
ChEMBL | Inhibition of FAM-labeled ZBA248 binding to recombinant human N-terminal His6-tagged BRD4 bromodomain 1 (44 to 168 residues) expressed in Rosetta2 DE3 cells after 30 mins by Flourescence polarization assay | B | 7.33 | pIC50 | 46.7 | nM | IC50 | J Med Chem (2017) 60: 3887-3901 [PMID:28463487] |
ChEMBL | Inhibition of BRD4 BD2 (unknown origin) incubated for 2 hrs by TR-FRET assay | B | 7.36 | pIC50 | 44 | nM | IC50 | J Med Chem (2021) 64: 18025-18053 [PMID:34908415] |
ChEMBL | Displacement of tetra-acetylated histone H4 peptide (1-21) from recombinant human N-terminal His-tagged BRD4 BD1 (44 to 170 residues) expressed in Escherichia coli incubated for 30 mins followed by further incubation with tetra-acetylated histone H4 peptide (1-21) for 30 mins by Alphascreen assay | B | 7.37 | pIC50 | 42.24 | nM | IC50 | J Med Chem (2019) 62: 11080-11107 [PMID:31789032] |
ChEMBL | Inhibition of FAM-labeled ZBA248 binding to recombinant human N-terminal His6-tagged BRD4 bromodomain 2 (333 to 460 residues) expressed in Rosetta2 DE3 cells after 30 mins by Flourescence polarization assay | B | 7.37 | pIC50 | 42.2 | nM | IC50 | J Med Chem (2017) 60: 3887-3901 [PMID:28463487] |
ChEMBL | Inhibition of FAM-labeled ZBA248 binding to recombinant N-terminal His6-tagged BRD4 bromodomain 2 (333 to 460 residues) (unknown origin) expressed in Escherichia coli Rosetta2 DE3 after 30 mins by fluorescence polarization assay | B | 7.37 | pIC50 | 42.2 | nM | IC50 | J Med Chem (2018) 61: 462-481 [PMID:28339196] |
ChEMBL | Inhibition of BRD4-BD1 (unknown origin) preincubated for 15 mins followed by substrate addition and measured after 1 hr | B | 7.38 | pIC50 | 42 | nM | IC50 | Bioorg Med Chem (2021) 39: 116133-116133 [PMID:33862375] |
ChEMBL | Inhibition of BRD4 bromodomain1 (unknown origin) using peptide histone H4 (SGRGACKGGACKGLGAC-KGGAACKRHGSGSK-biotin) as substrate incubated for 15 mins followed by substrate addition measured after 1 hr by alphascreen assay | B | 7.38 | pIC50 | 42 | nM | IC50 | ACS Med Chem Lett (2020) 11: 2174-2181 [PMID:33214826] |
ChEMBL | Inhibition of N-terminal His-tagged BRD4 (BD2) (unknown origin) using biotinylated tetra-acetylated histone H4 peptide after 30 mins by alpha-screen assay | B | 7.4 | pIC50 | 40 | nM | IC50 | J Med Chem (2018) 61: 8202-8211 [PMID:30165024] |
ChEMBL | Inhibition of recombinant human His-tagged BRD4 bromodomain 1/2 (2 to 1362 residues) expressed in s9f insect cells using biotinylated H4(1 to 21)K5/8/12/16Ac peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins by Alpha screen assay | B | 7.4 | pIC50 | 40 | nM | IC50 | Eur J Med Chem (2019) 179: 502-514 [PMID:31276895] |
ChEMBL | Displacement of (+)-JQ1 from 6H-Thr BRD4 Y390A mutant BD1 (unknown origin) after 30 mins by TR-FRET assay | B | 7.4 | pIC50 | 39.81 | nM | IC50 | J Med Chem (2018) 61: 4317-4334 [PMID:29656650] |
ChEMBL | Binding affinity to recombinant human N-terminal His-tagged BRD4 BD2 (349 to 460 residues) expressed in Escherichia coli measured after 30 mins by AlphaScreen assay | B | 7.41 | pIC50 | 39.09 | nM | IC50 | Bioorg Med Chem (2020) 28: 115181-115181 [PMID:31767403] |
ChEMBL | Displacement of FAM-labeled ZBA248 from BRD4 BD2 (333 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay | B | 7.45 | pIC50 | 35.7 | nM | IC50 | J Med Chem (2015) 58: 4927-4939 [PMID:26080064] |
ChEMBL | Inhibition of BRD4 bromodomain 2 (unknown origin)-acetylated histone H4 interaction by luminescence proximity homogeneous assay | B | 7.48 | pIC50 | 33 | nM | IC50 | Medchemcomm (2012) 3: 123-134 |
ChEMBL | Inhibition of BRD4 (unknown origin) | B | 7.48 | pIC50 | 33 | nM | IC50 | Bioorg Med Chem Lett (2017) 27: 4051-4055 [PMID:28765013] |
ChEMBL | Inhibition of recombinant human His6-tagged BRD4 bromodomain 2 expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells preincubated for 30 mins followed by HSGRGK(Ac)GGK(Ac)GLGK(Ac)GGAK(Ac)RHRK(Biotin)-OH peptide substrate addition after 30 mins by alphascreen assay | B | 7.48 | pIC50 | 33 | nM | IC50 | J Med Chem (2017) 60: 4533-4558 [PMID:28195723] |
ChEMBL | Inhibition of human recombinant N-terminal 6his-tagged BRD4 expressed in Escherichia coli BL21(DE3) using H4 peptide as substrate by alphascreen assay | B | 7.48 | pIC50 | 33 | nM | IC50 | Bioorg Med Chem Lett (2019) 29: 126577-126577 [PMID:31421967] |
ChEMBL | Inhibition of human C-terminal BRD4 bromodomain expressed in Escherichia coli BL21(DE3) after 30 mins by luminescence proximity homogeneous assay | B | 7.48 | pIC50 | 33 | nM | IC50 | J Med Chem (2012) 55: 587-596 [PMID:22136469] |
ChEMBL | Inhibition of human His-tagged BRD4 BD2 domain using H-SGRGK(Ac)GGK(Ac)GLGK-(Ac)GGAK(Ac)RHRK(Biotin)-OH as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by AlphaScreen assay | B | 7.48 | pIC50 | 33 | nM | IC50 | Eur J Med Chem (2020) 208: 112780-112780 [PMID:32883643] |
ChEMBL | Displacement of acetylated histone peptide from BRD4-BD2 by luminescence proximity homogenous assay | B | 7.48 | pIC50 | 33 | nM | IC50 | Bioorg Med Chem (2012) 20: 1887-1892 [PMID:22316554] |
ChEMBL | Inhibition of BRD4-BD1 (unknown origin) incubated for 1 hr by AlphaScreen biotin-JQ1 competition assay | B | 7.49 | pIC50 | 32 | nM | IC50 | J Med Chem (2018) 61: 7785-7795 [PMID:30125504] |
ChEMBL | Inhibition of recombinant BRD4 BD1 (unknown origin) incubated for 120 mins by TR-FRET assay | B | 7.54 | pIC50 | 29 | nM | IC50 | J Med Chem (2021) 64: 17413-17435 [PMID:34813314] |
ChEMBL | Displacement of FAM-labeled ZBA248 from BRD4 BD1 (44 to 168 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay | B | 7.54 | pIC50 | 28.7 | nM | IC50 | J Med Chem (2015) 58: 4927-4939 [PMID:26080064] |
ChEMBL | Displacement of FITC-JQ1 from His6-tagged BRD4 bromodomain-1 (unknown origin) expressed in Escherichia coli BL21(DE3) after 4 hrs by fluorescence anisotropy method | B | 7.55 | pIC50 | 28.5 | nM | IC50 | Eur J Med Chem (2018) 150: 156-175 [PMID:29525435] |
ChEMBL | Displacement of 5-FITC labelled (+)-JQ1 from His6-tagged human BRD4 bromodomain 1 expressed in Escherichia coli BL21(DE3) )-codon plus-RIL cells incubated for 4 hrs in dark condition by fluorescence anisotropy binding assay | B | 7.55 | pIC50 | 28.5 | nM | IC50 | J Med Chem (2019) 62: 8642-8663 [PMID:31490070] |
ChEMBL | Inhibition of recombinant human GST-tagged BRD4 BD1 (44 to 168 residues) expressed in Escherichia coli incubated for 60 mins by alphascreen assay | B | 7.55 | pIC50 | 27.9 | nM | IC50 | Bioorg Med Chem (2020) 28: 115228-115228 [PMID:31813613] |
ChEMBL | Displacement of tetra-acetylated histone H4 peptide (1-21) from recombinant human N-terminal His-tagged BRD4 BD2 (349 to 460 residues) expressed in Escherichia coli incubated for 30 mins followed by further incubation with tetra-acetylated histone H4 peptide (1-21) for 30 mins by Alphascreen assay | B | 7.61 | pIC50 | 24.71 | nM | IC50 | J Med Chem (2019) 62: 11080-11107 [PMID:31789032] |
ChEMBL | Displacement of biotinylated tetra-acetylated histone H4 from human his-tagged BRD4 bromodomain1 by alphascreen assay | B | 7.62 | pIC50 | 24 | nM | IC50 | J Med Chem (2016) 59: 1271-1298 [PMID:26572217] |
ChEMBL | Inhibition of His/FLAG-tagged BRD4 BD1 (unknown origin) using histone H4-TetraAcetylated-biotin peptide as substrate incubated for 20 mins by AlphaLISA assay | B | 7.62 | pIC50 | 24 | nM | IC50 | ACS Med Chem Lett (2016) 7: 145-150 [PMID:26985289] |
ChEMBL | Inhibition of His-FLAG-tagged BRD4 binding domain1 (unknown origin) binding to H4-TetraAc-biotin peptide after 20 mins by AlphaLISA | B | 7.62 | pIC50 | 24 | nM | IC50 | ACS Med Chem Lett (2013) 4: 835-840 [PMID:24900758] |
ChEMBL | Inhibition of human recombinant His-tagged BRD4 BD1 domain using H-SGRGK(Ac)GGK(Ac)GLGK-(Ac)GGAK(Ac)RHRK(Biotin)-OH as substrate preincubated with enzyme for 30 mins followed by substrate addition measured after 30 mins by AlphaScreen assay | B | 7.66 | pIC50 | 22 | nM | IC50 | J Med Chem (2020) 63: 3678-3700 [PMID:32153186] |
ChEMBL | Binding affinity to human BRD4 BD1 (44 to 168 residues) by fluorescence polarization assay | B | 7.66 | pIC50 | 22 | nM | IC50 | J Med Chem (2018) 61: 6685-6704 [PMID:30019901] |
ChEMBL | Inhibition of human BRD4 BD2 (342 to 460 residues) at 30 uM preincubated for 30 mins followed by substrate addition measured after 30 mins by TR-FRET assay | B | 7.68 | pIC50 | 21 | nM | IC50 | Eur J Med Chem (2016) 121: 294-299 [PMID:27266999] |
ChEMBL | Alpha Assay: BRD4(1): Assays were performed as described previously with minor modifications from the manufacturer's protocol (PerkinElmer, USA). All reagents were diluted in 50 mM HEPES, 100 mM NaCl, 0.1% BSA, pH 7.4 supplemented with 0.05% CHAPS and allowed to equilibrate to room temperature prior to addition to plates. A 24-point 1:2 serial dilution of the ligands was prepared over the range of 150-0 μM and 4 μl transferred to low-volume 384-well plates (ProxiPlate™-384 Plus, PerkinElmer, USA), followed by 4 μl of HIS-tagged protein (BRD4/1, 250 nM, BRD4/2 and CREBBP, 2000 nM). Plates were sealed and incubated at room temperature for 30 minutes, before the addition of 4 μl of biotinylated peptide at equimolar concentration to the protein [peptide for BRD4(1) & BRD4(2): H4K5acK8acK12acK16ac, H-SGRGK(Ac)GGK(Ac)GLGK(Ac)GGAK(Ac)RHRK(Biotin)-OH (SEQ ID NO: 5); peptide for CREBBP: H3K36ac, Biotin-KSAPATGGVK(Ac)KPHRYRPGT-OH (SEQ ID NO: 6) (Cambridge Research Biochemicals, UK)]. Plates were sealed and incubated for a further 30 minutes, before the addition of 4 μl of streptavidin-coated donor beads (25 μg/ml) and 4 μl nickel chelate acceptor beads (25 μg/ml) under low light conditions. Plates were foil-sealed to protect from light, incubated at room temperature for 60 minutes and read on a PHERAstar FS plate reader (BMG Labtech, Germany) using an AlphaScreen 680 excitation/570 emission filter set. IC50 values were calculated in Prism 5 (GraphPad Software, USA) after normalization against corresponding DMSO controls and are given as the final concentration of compound in the 20 μl reaction volume. | B | 7.74 | pIC50 | 18 | nM | IC50 | US-9320741-B2. Compositions and methods for treating neoplasia, inflammatory disease and other disorders (2016) |
ChEMBL | Alpha Assay: BRD4(2): Assays were performed as described previously with minor modifications from the manufacturer's protocol (PerkinElmer, USA). All reagents were diluted in 50 mM HEPES, 100 mM NaCl, 0.1% BSA, pH 7.4 supplemented with 0.05% CHAPS and allowed to equilibrate to room temperature prior to addition to plates. A 24-point 1:2 serial dilution of the ligands was prepared over the range of 150-0 μM and 4 μl transferred to low-volume 384-well plates (ProxiPlate™-384 Plus, PerkinElmer, USA), followed by 4 μl of HIS-tagged protein (BRD4/1, 250 nM, BRD4/2 and CREBBP, 2000 nM). Plates were sealed and incubated at room temperature for 30 minutes, before the addition of 4 μl of biotinylated peptide at equimolar concentration to the protein [peptide for BRD4(1) & BRD4(2): H4K5acK8acK12acK16ac, H-SGRGK(Ac)GGK(Ac)GLGK(Ac)GGAK(Ac)RHRK(Biotin)-OH (SEQ ID NO: 5); peptide for CREBBP: H3K36ac, Biotin-KSAPATGGVK(Ac)KPHRYRPGT-OH (SEQ ID NO: 6) (Cambridge Research Biochemicals, UK)]. Plates were sealed and incubated for a further 30 minutes, before the addition of 4 μl of streptavidin-coated donor beads (25 μg/ml) and 4 μl nickel chelate acceptor beads (25 μg/ml) under low light conditions. Plates were foil-sealed to protect from light, incubated at room temperature for 60 minutes and read on a PHERAstar FS plate reader (BMG Labtech, Germany) using an AlphaScreen 680 excitation/570 emission filter set. IC50 values were calculated in Prism 5 (GraphPad Software, USA) after normalization against corresponding DMSO controls and are given as the final concentration of compound in the 20 μl reaction volume. | B | 7.85 | pIC50 | 14 | nM | IC50 | US-9320741-B2. Compositions and methods for treating neoplasia, inflammatory disease and other disorders (2016) |
ChEMBL | Inhibition of BRD4 BD1 (unknown origin) preincubated for 15 mins followed by peptide addition and measured after 60 mins by TR-FRET assay | B | 7.92 | pIC50 | 12 | nM | IC50 | Eur J Med Chem (2020) 208: 112780-112780 [PMID:32883643] |
ChEMBL | Inhibition of BRD4 bromodomain-1 (unknown origin) by europium based LANCE TR-FRET assay | B | 8.1 | pIC50 | 8 | nM | IC50 | Bioorg Med Chem (2015) 23: 953-959 [PMID:25678016] |
ChEMBL | Inhibition of BRD4 BD2 (unknown origin) preincubated for 15 mins followed by peptide addition and measured after 60 mins by TR-FRET assay | B | 8.41 | pIC50 | 3.9 | nM | IC50 | Eur J Med Chem (2020) 208: 112780-112780 [PMID:32883643] |
ChEMBL | Inhibition of BRD4 in human H1299 cells assessed as decrease in HPV LCR-E2-EP400-mediated transcriptional repression after 24 hrs by Bright-Glo luciferase reporter gene assay | B | 6.82 | pEC50 | 153 | nM | EC50 | J Med Chem (2017) 60: 8369-8384 [PMID:28949521] |
ChEMBL | Inhibition of BRD4 in human MX1 cells assessed as decrease in cell proliferation after 3 days by Celltiter-Glo assay | B | 6.84 | pEC50 | 144 | nM | EC50 | Medchemcomm (2019) 10: 974-984 [PMID:31303996] |
ChEMBL | Inhibition of BRD4 in human H1229 cells transfected with HPV-E2 assessed as transrepression of HPV-long control region by luciferase reporter assay | B | 7.19 | pEC50 | 64 | nM | EC50 | Medchemcomm (2019) 10: 974-984 [PMID:31303996] |
bromodomain testis associated/Bromodomain testis-specific protein in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1795185] [GtoPdb: 2729] [UniProtKB: Q58F21] | ||||||||
ChEMBL | Binding affinity to recombinant human N-terminal hexaHis-tagged BRDT expressed in Escherichia coli BL21 (DE3) cells by MST assay | B | 6.59 | pKd | 260 | nM | Kd | J Med Chem (2021) 64: 15772-15786 [PMID:34710325] |
ChEMBL | Binding affinity to recombinant BRDT BD2 (unknown origin) incubated for 1 hr by TR-FRET assay | B | 6.66 | pKd | 217 | nM | Kd | J Med Chem (2020) 63: 5242-5256 [PMID:32255647] |
ChEMBL | Binding affinity to BRDT-BD1 by isothermal titration calorimetry | B | 6.72 | pKd | 190.1 | nM | Kd | Bioorg Med Chem (2012) 20: 1887-1892 [PMID:22316554] |
ChEMBL | Binding affinity to recombinant human N-terminal hexaHis-tagged BRDT expressed in Escherichia coli BL21 (DE3) cells by ITC analysis | B | 6.73 | pKd | 188 | nM | Kd | J Med Chem (2021) 64: 15772-15786 [PMID:34710325] |
ChEMBL | Binding affinity to recombinant BRDT BD1 (unknown origin) incubated for 1 hr by TR-FRET assay | B | 6.74 | pKd | 183 | nM | Kd | J Med Chem (2020) 63: 5242-5256 [PMID:32255647] |
ChEMBL | Binding affinity to recombinant human N-terminal hexaHis-tagged BRDT expressed in Escherichia coli BL21 (DE3) cells by qPCR assay | B | 7.66 | pKd | 22 | nM | Kd | J Med Chem (2021) 64: 15772-15786 [PMID:34710325] |
ChEMBL | Inhibition of recombinant BRDT BD1 (unknown origin) incubated for 120 mins by TR-FRET assay | B | 6.23 | pIC50 | 588 | nM | IC50 | J Med Chem (2021) 64: 17413-17435 [PMID:34813314] |
ChEMBL | Inhibition of recombinant BRDT BD2 (unknown origin) incubated for 120 mins by TR-FRET assay | B | 6.49 | pIC50 | 325 | nM | IC50 | J Med Chem (2021) 64: 17413-17435 [PMID:34813314] |
ChEMBL | Binding affinity BRDT BD2 (unknown origin) incubated for 1 hr by TR-FRET assay | B | 6.65 | pIC50 | 224 | nM | IC50 | J Med Chem (2022) 65: 2388-2408 [PMID:34982556] |
ChEMBL | Inhibition of BRDT BD2 (unknown origin) after 1 hr by TR-FRET assay | B | 6.66 | pIC50 | 217 | nM | IC50 | Eur J Med Chem (2018) 151: 450-461 [PMID:29649741] |
ChEMBL | Inhibition of BRDT BD1 (unknown origin) incubated for 2 hrs by TR-FRET assay | B | 6.68 | pIC50 | 207 | nM | IC50 | J Med Chem (2021) 64: 18025-18053 [PMID:34908415] |
ChEMBL | Inhibition of BRDT BD2 (unknown origin) incubated for 2 hrs by TR-FRET assay | B | 6.73 | pIC50 | 185 | nM | IC50 | J Med Chem (2021) 64: 18025-18053 [PMID:34908415] |
ChEMBL | Inhibition of BRDT BD1 (unknown origin) after 1 hr by TR-FRET assay | B | 6.74 | pIC50 | 183 | nM | IC50 | Eur J Med Chem (2018) 151: 450-461 [PMID:29649741] |
ChEMBL | Binding affinity BRDT BD1 (unknown origin) incubated for 1 hr by TR-FRET assay | B | 6.75 | pIC50 | 178 | nM | IC50 | J Med Chem (2022) 65: 2388-2408 [PMID:34982556] |
ChEMBL | Inhibition of human recombinant His-tagged BRDT BD1 domain expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells by AlphaScreen assay | B | 6.87 | pIC50 | 134 | nM | IC50 | J Med Chem (2020) 63: 3678-3700 [PMID:32153186] |
ChEMBL | Inhibition of BRDT D1 (unknown origin) by competitive fluorescence anisotropy assay | B | 6.92 | pIC50 | 120 | nM | IC50 | J Med Chem (2022) 65: 2342-2360 [PMID:35007061] |
ChEMBL | Inhibition of BRDT-BD1 (unknown origin) incubated for 1 hr by AlphaScreen biotin-JQ1 competition assay | B | 6.99 | pIC50 | 103 | nM | IC50 | J Med Chem (2018) 61: 7785-7795 [PMID:30125504] |
GtoPdb | Inhibition of H4Kac4 binding to hBRDT-BD1 | - | 7.96 | pIC50 | 11 | nM | IC50 | Cell (2012) 150: 673-84 [PMID:22901802] |
bromodomain testis associated in Mouse [GtoPdb: 2729] [UniProtKB: Q91Y44] | ||||||||
GtoPdb | Inhibition of H4Kac4 binding to mBRDT-BD1 | - | 8 | pIC50 | 10 | nM | IC50 | Cell (2012) 150: 673-84 [PMID:22901802] |
CREB binding protein/CREB-binding protein in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5747] [GtoPdb: 2734] [UniProtKB: Q92793] | ||||||||
ChEMBL | Binding affinity to recombinant CBP (unknown origin) incubated for 1 hr by TR-FRET assay | B | 5.02 | pKd | 9600 | nM | Kd | J Med Chem (2020) 63: 5242-5256 [PMID:32255647] |
ChEMBL | Displacement of acetylated histone peptide from CREBBP by luminescence proximity homogenous assay | B | 5 | pIC50 | >10000 | nM | IC50 | Bioorg Med Chem (2012) 20: 1887-1892 [PMID:22316554] |
ChEMBL | Inhibition of CBP (unknown origin) after 1 hr by TR-FRET assay | B | 5.02 | pIC50 | 9600 | nM | IC50 | Eur J Med Chem (2018) 151: 450-461 [PMID:29649741] |
ChEMBL | Binding affinity CBP (unknown origin) incubated for 1 hr by TR-FRET assay | B | 5.02 | pIC50 | 9546 | nM | IC50 | J Med Chem (2022) 65: 2388-2408 [PMID:34982556] |
E1A binding protein p300/Histone acetyltransferase p300 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3784] [GtoPdb: 2735] [UniProtKB: Q09472] | ||||||||
ChEMBL | Inhibition of P300 (unknown orign) using acetyl-CoA as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by microplate reader analysis | B | 4.71 | pIC50 | 19400 | nM | IC50 | J Med Chem (2021) 64: 17413-17435 [PMID:34813314] |
ChEMBL data shown on this page come from version 33:
Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, Félix E, Magariños MP, Mosquera JF, Mutowo P, Nowotka M, Gordillo-Marañón M, Hunter F, Junco L, Mugumbate G, Rodriguez-Lopez M, Atkinson F, Bosc N, Radoux CJ, Segura-Cabrera A, Hersey A, Leach AR. (2019) 'ChEMBL: towards direct deposition of bioassay data' Nucleic Acids Res., 47(D1). DOI: 10.1093/nar/gky1075. [EPMCID:30398643]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]